Consultant in Infectious Diseases & General Medicine

Research Interests:

Infectious Diseases

Projects/ grants:

Principal Investigator: 'Study To Compare The Immunogenicity Against COVID-19, Of VLA2001 Vaccine To AZD1222 Vaccine (COV-COMPARE)'


Dr Iain Page is a Consultant in Infectious Diseases & General Medicine at the Western General Hospital in Edinburgh. He has a sub-specialist interest in Fungal Infections and in particular Chronic Pulmonary Aspergillosis (CPA) and is establishing a clinical service for CPA patients in collaboration with respiratory physician colleagues. He is also engaged in COVID-19 research and is Principal Investigator for the Valneva COVID vaccine trial and an Investigator for the Oxford vaccine trial and RECOVERY therapeutics trials in Edinburgh.

He completed medical school and junior doctor training in Edinburgh. From 2007 he combined specialist training in Infectious Diseases in Manchester with several years teaching and leading research projects in Malawi and Uganda. He completed his PhD on Chronic Pulmonary Aspergillosis in 2015 and was subsequently an Academic Clinical Lecturer at the UK National Aspergillosis Centre in Manchester, before returning to Edinburgh in 2020. He is secretary of CPANet, the European clinical network for CPA research.

Key Publications:


Chronic pulmonary aspergillosis commonly complicates treated pulmonary tuberculosis with residual cavitation. Page ID,  Byanyima R, Hosmane S, Onyachi N, Opira C, Richardson M, Sawyer R, Sharman A, Denning DW. European Respiratory Journal2019. DOI: 10.1183/13993003.01184-2018 


Case Definition of Chronic Pulmonary Aspergillosis in Resource-ConstrainedSettings. Denning DW, Page ID, Chakaya J, Chakrabarti A, …27 others… Cole DC, Haileyesus G Emerging Infectious Diseases. 2018 Aug;24(8). doi: 10.3201/eid2408.171312. 


A CPAnet consensus statement on research priorities for chronic pulmonary aspergillosis: a neglected fungal infection that requires attention. Godet C … Page ID, Seidel D, Salzer H. Journal of Antimicrobial Chemotherapy. 2017. doi:10.1093/jac/dkx390. 


Comparison of six Aspergillus-specific IgG assays for the diagnosis of chronic pulmonary aspergillosis (CPA). Page I, Richardson M, Denning DW.  Journal of Infection. 2016;72(2):240-9. 


International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigates. Verweij P… Page I et.al. Drug Resistance Updates2015;21-22:30-40. doi: 10.1016/j.drup.2015.08.001

All Publications:


Role of serological tests in the diagnosis of mold infections.. Richardson M & Page ID.  Current Fungal Infection Reports 2018. Sept 5. https://doi.org/10.1007/s12281-018-0321-1. 

Treatment of chronic pulmonary aspergillosis: current standards and future perspectives. Alastruey-Izquierdo A, … Page ID, Salzer HJF et al on behalf of CPAnet.  Respiration. 2018 doi:10.1159/000489474

Siemens Immulite Aspergillus-specific IgG assay for chronic pulmonary aspergillosis diagnosis. Page ID, Richardson M & Denning DW. Medical Mycology. 2018. doi:10.1093/mmy/myy024.

Receiver operating characteristic curve analysis of four Aspergillus-specific IgG assays for the diagnosis of chronic pulmonary aspergillosis. Page ID, Baxter C, Hennequin C, Richardson M, van Hoeyveld E, van Toorenenbergen A, Denning D. Diagnostic Microbiology and Infectious Diseases. 2018. https:doi.org/10.1016/j.diagmicrobio.2018.01.001. 


Elevated Aspergillus-specific antibody levels among HIV-infected Ugandans with pulmonary tuberculosis. Kwizera R, Ratanshi R, Page I et al. BMC Pulmonary Medicine. 2017(17):149. 

Aspergillus serology – have we arrived yet? Richardson MD & Page IDMedical Mycology. 2017 1;55(1):48-55 doi: 10.1093/mmy/myw116. 


Aspergillus nodules; another presentation of Chronic Pulmonary Aspergillosis. Muldoon, EG, Sharman A, Page I, Bishop P, Denning DW.  BMC Pulmonary Medicine. 2016. 


Antibody testing in aspergillosis – quo vadis? Page ID, Richardson M, Denning D. Medical Mycology. 2015. 53(5): 417-439. doi:10.1093/mmy/myv020


Screening HIV infected adults in Malawi for anaemia: need for a new haemoglobin threshold to determine eligibility for antiretroviral therapy. Page I, McKew S, Kudzala A, Fullwood C, van Oosterhout J and Bates I.  International Journal of STD & AIDS. 2013; 24(6): 449-53. 


The impact of new National HIV Testing Guidelines at a District General Hospital in an area of high HIV sero-prevalencePage I, Phillips M, Flegg P, Palmer R. Journal of the Royal College of Physicians of Edinburgh. 2011, 41:9-12.

Implementing the Surviving Sepsis Guidelines in a District General Hospital. Page I, Hardy GD, Fairfield J, Orr D, Nichani R. Journal of the Royal College of Physicians of Edinburgh 2011; 41:309-15.